caselaw.findlaw.com/pa-superior-court/1889831.html

JANSSEN PHARMACEUTICALS INC JOHNSON JOHNSON JANSSEN ... JANSSEN RESEARCH AND DEVELOPMENT, LLC NICHOLAS MURRAY, Appellant v. ... All of the cases in this mass tort action consist of male plaintiffs who allege they ...... 682, 42 U.S.C. § 201 et seq. and was approved or licensed; or is generally ...

www.law360.com/cases/5c9545fde9b2183d0d69666f

Parties, docket activity and news coverage of federal case Buchanan v. ... RESEARCH AND DEVELOPMENT LLC et al, case number 2:19-cv-02806, from  ...

www.law360.com/judges/eldon-e-fallon

March 22, 2019 | Louisiana Eastern Hill v. Janssen Research & Development LLC et al. 367(Personal Injury: Health Care/Pharmaceutical Personal Injury ...

www.litigationandtrial.com/files/2016/06/Invokana-Janssen-Response.pdf

Oct 12, 2016 ... In Brazil v. Janssen Research & Development LLC, No. ..... vs. Janssen Pharmaceuticals, Inc., et al.; In the United States District Court for the.

www.janssen.com/research-and-development

See how Janssen tackles research and development of new drug treatments and therapies.

www.ncbi.nlm.nih.gov/pubmed/23412078

Feb 14, 2013 ... (1)Janssen Research & Development, LLC, San Diego, California, USA. ... 0- to 6 -h urinary glucose excretion (UGE0-6h, 18.2 ± 5.6 vs. <0.2 g ...

www.ncbi.nlm.nih.gov/pubmed/24939043

Jul 8, 2014 ... Sha S(1), Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, ... (1)Janssen Research & Development, LLC, Raritan, NJ, USA. ... compared with a reduction in the placebo group at both week 1 (91.8 vs.

www.ncbi.nlm.nih.gov/pubmed/25421015

Jan 5, 2015 ... Sha S(1), Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, ... (1)Janssen Research & Development, LLC, Raritan, NJ, USA. ... Mean 24-h UGE was ∼25% higher with canagliflozin than with dapagliflozin (51.4 vs. 40.8 g) ...